InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,277.51
(
0.80%
)
US TECH 100
18,064.80
(
0.02%
)
Dow Jones
38,686.32
(
1.51%
)
Brent Oil
81.30
(
0.00%
)
Bitcoin
67,753.00
(
0.40%
)
Post# of 252007
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 830
Posts 119741
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 39447

Tuesday, 11/20/2007 7:22:46 AM

Tuesday, November 20, 2007 7:22:46 AM

Post# of 252007
Genmab, GSK Start Phase-3 RA Trial
for Second-Generation CD20 Drug

http://www.reuters.com/article/marketsNews/idUKL204181720071120

>>
Tue Nov 20, 2007 3:36am EST

COPENHAGEN, Nov 20 (Reuters) - Danish biotech firm Genmab (GEN.CO) said on Tuesday it would start Phase III trials with ofatumumab for the treatment of rheumatoid arthritis. The trial will begin with two studies outside the United States in distinct patient populations. It will entail a 24-week double-blind period followed by a 120-week open-label period.

It will be conducted in partnership with Britain's GlaxoSmithKline (GSK).

One patient group has had an inadequate response to methotrexate therapy, while the other has had an inadequate response to TNF-alpha antagonist therapy.

Ofatumumab, also known as HuMax-CD20, is an experimental antibody drug also being tested for leukaemia and other blood cancers.

Glaxo bought global rights to HuMax-CD20 in a deal worth up to $2.1 billion last December.
<<

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up